Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries shows that 15% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 38% earn between 1 million and 2 million yuan, 4% earn between 2 million and 3 million yuan, and 2% earn above 3 million yuan [5] Age and Educational Background - The majority of company secretaries (61%) are aged between 40 and 50 years, while 15% are over 50, 18% are between 30 and 40, and 6% are 30 or younger [1] - In terms of education, 52% hold a bachelor's degree, 44% have a master's degree, and only 2% have a doctoral degree, with master's and above accounting for over half of the total [3] Investor Engagement - There is a wide variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [7] - The top five companies with the highest number of investor meetings include Bohui Innovation, Jindike, Nearshore Protein, Sailun Biotech, and Kanghua Biotech, with meeting counts of 1,500, 777, 681, 549, and 504 respectively [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those aged 30-40 make up 18% [1] - In terms of education, 52% of secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% possess a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan, with the distribution of salaries as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] - The top five highest-paid company secretaries have salaries of 3.2565 million yuan, 2.5345 million yuan, 2.2809 million yuan, 1.9265 million yuan, and 1.89 million yuan, with their tenure at the companies ranging from less than one year to 15 years [7] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those under 30 make up 6% [1][3] - The educational background indicates that 52% hold a bachelor's degree, 44% have a master's degree, and only 2% possess a doctoral degree, with the latter represented by just one individual [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [9] - The five companies with the highest number of investor meetings are reported to have 1,500, 777, 681, 549, and 504 meetings, respectively [9]

Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]

Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

Group 1 - The A-share biopharmaceutical sector experienced a significant afternoon rally, with notable increases in stock prices [1] - Zhifei Biological surged over 14%, while Watson Bio rose more than 12% [1] - Other companies such as Kangtai Biological, Sanyuan Gene, Bohui Innovation, Baike Biological, and Zhixiang Jintai also saw gains [1]

Group 1 - The company held its 11th meeting of the 8th Supervisory Board on June 27, 2025, with all three supervisors present, complying with legal and procedural requirements [1][2] - The Supervisory Board approved a proposal allowing the company and its subsidiaries to borrow up to RMB 1 billion from the related party, Wuhai Junzheng Technology Industry Group Co., Ltd., to meet operational needs and improve financing efficiency [1][2] - The borrowing will be at a rate not exceeding the People's Bank of China’s loan market quotation rate, without the need for guarantees or collateral, and will be used for daily operations, project construction, and other funding needs [1][2] Group 2 - The Supervisory Board concluded that borrowing from Junzheng Technology would meet the company's operational development needs, reduce financing costs, and maintain the interests of all shareholders without violating any laws or regulations [2] - The voting result for the proposal was unanimous, with 2 votes in favor and no opposition or abstentions, representing 100% of the total votes [2]

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-029 北京博晖创新生物技术集团股份有限公司 关于公司向关联方借款暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 于 2025 年 6 月 27 日召开第八届董事会第十二次会议、第八届监事会第十一次会 议，审议通过了《关于公司向关联方借款暨关联交易的议案》，现就相关事项公 告如下： 一、关联交易概述 为满足生产经营需求，提高融资效率，公司及合并范围内各下属公司可根据 各自经营需要向关联方乌海市君正科技产业集团有限责任公司（以下简称"君正 科技"）申请借款，借款额度不超过人民币10亿元。公司及合并范围内各下属公 司可根据实际需要在借款额度内分批次循环使用。借款利率不高于中国人民银行 规定的贷款市场报价利率，无需提供保证、抵押、质押等任何形式的担保。上述 借款将用于日常经营、项目建设及其他资金需求。 君正科技为公司实际控制人杜江涛先生控制的企业，根据《深圳证券交易所 创业板股票上市规则》的相关规定，本次交易构 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-028 北京博晖创新生物技术集团股份有限公司 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第十一次会议于 2025 年 6 月 27 日在公司会议室召开，会议通知于 2025 年 6 月 16 日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司 监事会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议 应出席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和 《公司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《关于公司向关联方借款暨关联交易的议案》 为满足生产经营需求，提高融资效率，公司及合并范围内各下属公司可根据各 自经营需要向关联方乌海市君正科技产业集团有限责任公司申请借款，借款额度不 超过人民币 10 亿元。公司及合并范围内各下属公司可根据实际需要在借款额度内 分批次循环使用。借款利率不高于中国人民银行规定的贷款市场报价利率，无需提 供保证、抵押、质押等任何形式的担保。上述借款将用于日常经营、项目建设及其 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第十二次会议于 2025 年 6 月 27 日在公司会议室召开，会议通知于 2025 年 6 月 16 日以专人送达、邮件通知或电话通知的方式送达各位董事，会议 由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本次 会议应出席董事 7 人，实际出席董事 7 人，监事列席了会议。本次会议的召集召 开程序符合《公司法》和《公司章程》的有关规定。 证券代码：300318 证券简称：博晖创新 公告编号：临 2025-027 北京博晖创新生物技术集团股份有限公司 第八届董事会第十二次会议决议公告 本议案已经第八届董事会第三次独立董事专门会议审议通过。 1 二、董事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《关于公司向关联方借款暨关联交易的议案》 为满足生产经营需求，提高融资效率，公司及合并范围内各下属公司可根据 各自经营需要向关联方乌海市君正科技产业集团有限责任公司申请借款，借款额 ...